



## NIH AIDS Reagent Program

20301 Century Boulevard  
Building 6, Suite 200  
Germantown, MD 20874  
USA

Phone: 240 686 4740  
Fax: 301 515 4015  
aidsreagent.org

### DATA SHEET

<b>Reagent:</b>	Anti-HIV-1 gp120 Monoclonal (F105)
<b>Catalog Number:</b>	857
<b>Lot Number:</b>	050728
<b>Release Category:</b>	C
<b>Provided:</b>	100 µg at 1.6 mg/ml. Protein G-purified from tissue culture supernatant, quantitated by ELISA and dialyzed against PBS. The antibody is stable at this concentration. If a less concentrated stock is needed, dilute the material no further than 1 mg/ml, and use it within three months.
<b>Host Site:</b>	Human EBV-transformed B cell x HMMA2.11TG/O myeloma.
<b>Titer:</b>	Use 2 µg of antibody per million cells in flow cytometry and immunofluorescence assays, and 1-10 µg/ml for neutralization assays. Other applications will vary with the requirements of the experimental system.
<b>Special Characteristics:</b>	F105 reacts with a discontinuous, or conformational, gp120 epitope. Binds to gp120 on the surface of IIIB, SF2, MN, RF, and CC-infected cells. Neutralizes SF2, IIIB, and MN infection at concentrations ranging from 140 ng/ml to 10 µg/ml.
<b>Recommended Storage:</b>	Keep at 4°C for short term storage and -80°C for long term storage. Avoid freeze-thaw cycles as reagent degradation may result.
<b>Contributor:</b>	Dr. Marshall Posner and Dr. Lisa Cavacini.
<b>Isotype:</b>	IgG <sub>1</sub> , kappa.
<b>References:</b>	Posner MR, et al. <i>J Acquired Immune Defic Syndr</i> <b>6</b> :7-14, 1993. Cavacini LA, et al. <i>J Acquired Immune Defic Syndr</i> <b>6</b> :353-358, 1993. Posner MR, et al. <i>Hybridoma</i> <b>6</b> :611-625, 1987. Posner MR, et al. <i>J Immunol</i> <b>146</b> :4325-4332, 1991.

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.

**NOTE:**

Acknowledgment for publications should read "The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, NIAID, NIH: Anti-HIV-1 gp120 Monoclonal (F105) from Dr. Marshall Posner and Dr. Lisa Cavacini." Also include the references cited above in any publications. US Patent No. 5215913.

**Requests from commercial organizations should be directed to Jodi Hecht, Technology Ventures Office, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, BR2, Boston, MA 02215. Email: [jehecht@bidmc.harvard.edu](mailto:jehecht@bidmc.harvard.edu).**

**Last Updated**

May 18, 2015

---

ALL RECIPIENTS OF THIS MATERIAL MUST COMPLY WITH ALL APPLICABLE BIOLOGICAL, CHEMICAL, AND/OR RADIOCHEMICAL SAFETY STANDARDS INCLUDING SPECIAL PRACTICES, EQUIPMENT, FACILITIES, AND REGULATIONS. NOT FOR USE IN HUMANS.